https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36475 18 y. Where possible, studies were pooled for meta-analysis using RevMan 5.2. The principle summary measure was the mean difference between groups calculated using the random-effects model. Results: Eleven eligible crossover and 1 parallel trial were identified with a total of 299 participants [weighted mean ± SD age: 38 ± 3 y; weighted mean ± SD body mass index (kg/m²): 24 ± 2]. All studies were pooled for the meta-analysis. Diets enriched with MCFAs led to significantly higher high-density lipoprotein (HDL) cholesterol concentrations than diets enriched with LCSFAs (0.11 mmol/L; 95% CI: 0.07, 0.15 mmol/L) with no effect on triglyceride, low-density lipoprotein (LDL) cholesterol, and total cholesterol concentrations. Consumption of diets rich in MCFAs significantly increased apolipoprotein A-I (apoA-I) concentrations compared with diets rich in LCSFAs (0.08 g/L; 95% CI: 0.02, 0.14 g/L). There was no evidence of statistical heterogeneity for HDL cholesterol, apoA-I, and triglyceride concentrations; however, significant heterogeneity was observed for the total cholesterol (I² = 49%) and LDL cholesterol analysis (I² = 58%). Conclusion: The findings of this research demonstrate a differential effect of MCFAs and LCSFAs on HDL cholesterol concentrations. Further investigations are warranted to elucidate the mechanism by which the lipid profile is altered. This trial was registered at www.crd.york.ac.uk/PROSPERO as CRD42017078277.]]> Wed 24 Nov 2021 15:51:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35660 Wed 02 Mar 2022 14:23:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41980 Tue 16 Aug 2022 15:48:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45006 Thu 23 Mar 2023 13:24:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42118 Thu 18 Aug 2022 14:28:38 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32707 Thu 12 Jul 2018 11:51:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27700 Sat 24 Mar 2018 07:40:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22886 Sat 24 Mar 2018 07:15:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39179 Mon 23 May 2022 16:16:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47536 Mon 23 Jan 2023 12:22:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53955 Mon 22 Jan 2024 17:03:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40753 Mon 18 Jul 2022 13:40:24 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36438 Mon 04 May 2020 12:30:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46149 40 and Aβ₄₂ concentrations were measured using the ultrasensitive Single Molecule Array (Simoa) assay in 95 cognitively normal elderly individuals, who have all undergone PET to assess brain Aβ deposition. Based on the standard uptake value ratios (SUVR) obtained from PET imaging, using the tracer ¹⁸F-Florbetaben, plasma Aβ was compared between 32 participants assessed to have low brain Aβ load (Aβ–, SUVR <1.35) and 63 assessed to have high brain Aβ load (Aβ+, SUVR ≥1.35). Results: Plasma Aβ₄₂/Aβ₄₀ ratios were lower in the Aβ+ group compared to the Aβ–group. Plasma Aβ₄₀ and Aβ₄₂ levels were not significantly different between Aβ–and Aβ+ groups, although a trend of higher plasma Aβ₄₀ was observed in the Aβ+ group. Additionally, plasma Aβ₄₂/Aβ₄₀ ratios along with the known AD risk factors, age and APOE ɛ4 status, resulted in Aβ+ participants being distinguished from Aβ–participants based on an area under the receiver operating characteristic curve shown to be 78%. Conclusion: Plasma Aβ ratios in this study are a potential biomarker for brain Aβ deposition and therefore, for preclinical AD. However, this method to measure plasma Aβ needs further development to increase the accuracy of this promising AD blood biomarker.]]> Fri 11 Nov 2022 18:51:47 AEDT ]]>